NCT05817825 Pilot Testing a Novel Remotely Delivered Intensive Outpatient Program for Individuals With OUD
| NCT ID | NCT05817825 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brigham and Women's Hospital |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2023-11-17 |
| Primary Completion | 2024-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2023-11-17 with a primary completion date of 2024-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to test a remotely delivered IOP program ("SmartIOP") for OUD patients who are hospitalized for serious injection-related infections. This will be a pilot trial to assess the feasibility of the IOP program and examine OUD-related outcomes following discharge from the hospital.
Eligibility Criteria
Inclusion Criteria: * English-speaking adults aged 18 and above * Any DSM-5 substance use disorder * Can identify at least 2 individuals who can act as points of contact following discharge from the hospital Exclusion Criteria: * Psychotic disorder, active suicidality, or homicidally * Condition likely to be terminal during the study period * Unable to perform consent due to impaired mental status
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05817825 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05817825 currently recruiting?
Yes, NCT05817825 is actively recruiting participants. Contact the research team at jsuzuki2@bwh.harvard.edu for enrollment information.
Where is the NCT05817825 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05817825 clinical trial?
NCT05817825 is sponsored by Brigham and Women's Hospital. The trial plans to enroll 20 participants.